Address
The SchrOedinger Building
Oxford, OX4 4GE
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 18 6581 8941
Website
Sector
Healthcare
Industry
Biotechnology
Employees
483
First IPO Date
October 01, 2021
| Name | Title | Pay | Year Born |
| David Hallett | Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer & Executive Director | 0 | 1969 |
| Ben R. Taylor | Chief Financial Officer, Chief Strategy Officer & Executive Director | 558,080 | 1977 |
| Marie-Louise Helena Fjallskog | Interim Chief Medical Officer & Clinical Development Lead | 0 | 1964 |
| Dan Ireland | Executive Vice President of Legal & Company Secretary | 0 | N/A |
| Nikolaus Krall | Executive Vice President of Precision Medicine | 0 | N/A |
| Parker Moss | Executive Vice President of Corporate Development | 0 | N/A |
| Sara Sherman | Vice President of Investor Relations | 0 | N/A |
| Richard | Chief Business Officer | 0 | N/A |
| Caroline Rowland | Chief People Officer | 0 | N/A |
| John Overington | Chief Technology Officer | 0 | N/A |
Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.